argenx (ARGX) Stock Overview
A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ARGX from our risk checks.
ARGX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
argenx SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €571.23 |
| 52 Week High | €678.21 |
| 52 Week Low | €460.05 |
| Beta | 0.030 |
| 1 Month Change | 5.36% |
| 3 Month Change | -3.94% |
| 1 Year Change | 20.80% |
| 3 Year Change | 56.49% |
| 5 Year Change | 125.58% |
| Change since IPO | 2,383.61% |
Recent News & Updates
Recent updates
Argenx's CIDP Challenge: A Safety Signal Points To Operational Refinement, Not Ruin
Jun 30Argenx: The Magic May Be Already Priced In
Mar 24argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent
Feb 27argenx: Lofty Valuation Diminishes Appeal Amid Autoimmune Expansion (Rating Downgrade)
Jan 23Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat
Oct 31argenx: Myositis Data Could Add Billions In Value
Sep 25Argenx: Strong Setup For Outperformance In 2025
Jun 28argenx: Innovation Over Losses In Autoimmune Arena
May 07argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion
Feb 01Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod
Sep 21Argenx's neuromuscular disorder drug Vyvgart wins approval in EU
Aug 11Argenx SE GAAP EPS of -$3.81 beats by $0.83, total operating income of $85.18M
Jul 28argenx: A Very Good Start For Vyvgart
May 25argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain
May 18argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers
Mar 07argenx: Vyvgart's Approval A Key Step For Continued Value Creation
Dec 22argenx SE: Institutional Buying Turnaround In Dutch Biotech With Thin Audience Now Seen As Good Value By Market-Makers
Nov 30argenx: R&D Day Goes Unnoticed
Aug 23argenx: Next Phase Of Growth With Efgartigimod And ARGX-117
Jun 30Shareholder Returns
| ARGX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.7% | -1.7% | 0.8% |
| 1Y | 20.8% | -13.2% | 13.7% |
Return vs Industry: ARGX exceeded the US Biotechs industry which returned -13.2% over the past year.
Return vs Market: ARGX exceeded the US Market which returned 13.7% over the past year.
Price Volatility
| ARGX volatility | |
|---|---|
| ARGX Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ARGX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ARGX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,599 | Tim Van Hauwermeiren | argenx.com |
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy.
argenx SE Fundamentals Summary
| ARGX fundamental statistics | |
|---|---|
| Market cap | US$34.99b |
| Earnings (TTM) | US$1.06b |
| Revenue (TTM) | US$2.64b |
Is ARGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARGX income statement (TTM) | |
|---|---|
| Revenue | US$2.64b |
| Cost of Revenue | US$1.33b |
| Gross Profit | US$1.31b |
| Other Expenses | US$246.52m |
| Earnings | US$1.06b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 31, 2025
| Earnings per share (EPS) | 17.39 |
| Gross Margin | 49.59% |
| Net Profit Margin | 40.26% |
| Debt/Equity Ratio | 0.7% |
How did ARGX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/22 21:47 |
| End of Day Share Price | 2025/07/22 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
argenx SE is covered by 49 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Charles Pitman | Barclays |
| Richard Parkes | BNP Paribas Exane |